Brief: Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of Fpi-1434
14/06/2022 23:12
Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS PRESENTS IMAGING DATA FROM COLD
ANTIBODY
SUB-STUDY IN THE PHASE 1 STUDY OF FPI-1434
* FUSION PHARMACEUTICALS INC - STUDY EVALUATES
PRE-ADMINISTRATION
OF COLD ANTIBODY PRIOR TO ADMINISTRATION OF IMAGING AGENT
* FUSION PHARMACEUTICALS INC - IMAGING SHOWS FAVORABLE GAIN
IN
TUMOR LESION UPTAKE VERSUS NORMAL TISSUE WHEN COLD ANTIBODY IS
PRE-ADMINISTERED
Source text for Eikon: ID:nCNWcdQRRa
Further company coverage: FUSN.O
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary